Racing a clock somebody else set: management describes an outside deadline already driving the company's current work
The model's full reasoning — Q4 2022 call → NOWe need answer YES/NO based on transcript. Need identify if management describes company currently working against externally-set dated deadline, visible work, payoff ahead. Let's parse. Key candidates: fazirsiran Phase 3 with Takeda. Takeda submitted Phase 3 protocol to FDA end of last quarter, waiting feedback. Takeda still on schedule to begin Phase 3 in first quarter of 2023. Arrowhead expects to report topline SEQUOIA data and guidance on Phase 3. Is there external date? FDA feedback expected soon, Phase 3 start Q1 2023. But is company working to that date? They are waiting for feedback, not necessarily racing. Also "Takeda is still on schedule to begin Phase 3 in first quarter of 2023" - external? Takeda's schedule. But company's own work? Not much. Another: 20 in '25 program - plan to have 20 drugs in clinical trials or market in 2025. That's internal target, not external deadline. Another: ARO-RAGE/MUC5AC interim data first half 2023 - internal guidance. Another: ARO-C3 interim data first half 2023 - internal. Another: next cell type announcement first half 2023 - internal. Another: end of Phase 2 meetings first half 2023, Phase 3 studies second half 2023 - internal. Another: Royalty Pharma deal - not deadline. Question asks "ON THIS CALL, does management describe the company as CURRENTLY WORKING AGAINST A DATED DEADLINE THAT SOMEBODY OUTSIDE THE COMPANY HAS SET — a fixed date, window, season, or schedule imposed by a customer, partner, program, authority, or event, which the company does not control and cannot move — AND is the company already visibly organizing its own operations around hitting that date, with the business it unlocks still ahead of the reported results?" Need find if any external fixed date. The only external date mentioned: Takeda submitted Phase 3 protocol to FDA, waiting feedback. Takeda on schedule to begin Phase 3 in Q1 2023. But is that a deadline company must hit? They plan to have update prior to that. But not necessarily "working against" with visible operations. Also "FDA feedback shortly" - external but not a date. Another: "We expect to report topline data from Phase 2 SEQUOIA study at same time we provide guidance on Phase 3 design. Ideally, Takeda and Arrowhead would do these together. Takeda submitted Phase 3 protocol to U.S. FDA at end of last quarter and is waiting for feedback.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| RCEL | AVITA Medical, Inc. | Q1 2024 | 2024-05-14 | F |
| RLX | RLX Technology Inc. | Q1 2022 | 2022-05-20 | C |
| AKBA | Akebia Therapeutics, Inc. | Q3 2021 | 2021-11-09 | C+ |
| EGY | VAALCO Energy, Inc. | Q2 2021 | 2021-08-12 | B |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| MKTX | MarketAxess Holdings Inc. | Q3 2017 | 2017-10-25 | C+ |
| AEHR | Aehr Test Systems | Q2 2017 | 2017-01-05 | F |
| WYY | WidePoint Corporation | Q3 2016 | 2016-11-09 | D |
RLX · Q1 2022 → YESThe question is about whether management describes the company as currently working against a dated deadline set by someone outside the company, organizing operations around hitting that date, with th...
AKBA · Q3 2021 → YESThe question is: Does management describe the company as CURRENTLY WORKING AGAINST A DATED DEADLINE THAT SOMEBODY OUTSIDE THE COMPANY HAS SET... and organizing operations around hitting that date, wit...
EGY · Q2 2021 → YESThe question is about whether management describes the company as currently working against a dated deadline set by someone outside the company, organizing operations around hitting that date, with th...